ReviewBreast cancer (Tokyo, Japan)2026
Niraparib in breast cancer: evidence-based perspective on translational progress.
Review in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most prevalent malignancy in women throughout the world, with a high level of heterogeneity concerning the subtypes, posing challenges to long-term treatment success. Among the emerging therapeutic strategies, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promise in targeting tumors with defects in homologous recombination repair, particularly those harbouring BRCA1/2 mutations. Niraparib, a highly potent selective PARP1/2 inhibitor administered orally, has demonstrated a high anti-tumor response in ovarian cancer and is currently undergoing clinical trials in breast cancer treatment. Though niraparib possesses structural and functional similarities to other approved agents such as olaparib and talazoparib, it is not yet approved for breast cancer. This serves as a research gap that requires critical consideration of its therapeutic positioning. This review offers an in-depth examination of pharmacological profile, mechanism of action, resistance mechanism, and the benefits of niraparib in BRCA-mutated homologous recombination deficient breast cancer. We also summarise findings from major clinical trials that assess niraparib as monotherapy and in combination with chemotherapy, immune checkpoint inhibitors, and radiotherapy. Furthermore, this review critically evaluates the safety profile, pharmacokinetics, and ongoing clinical studies. Besides these, this article highlights the translational horizons and a new combination strategy that can possibly expand the use of niraparib to a wider patient group. By bridging mechanistic science and clinical applications, this review highlights the potential of niraparib to unlock synthetic lethality and shape the future landscape of precision oncology in breast cancer.
Indexed as
Identifiers
41944954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.